Introduction {#sec1-1}
============

*Sthaulya* is included under eight undesirable conditions (*Ashtau Nindita*),\[[@ref1]\] *Shleshma Nanatmaja*,\[[@ref2]\] *Samtarpana Nimittaja*,\[[@ref3]\] *Atinindita*,\[[@ref4]\] *Ati Brihmana Nimittaja*\[[@ref5]\] and *Bahu Dosha Janita*\[[@ref6]\] *Vikara*. Moreover *Sushruta* has emphasized on metabolic disturbances (*Dhatvaagnimandya*) in the etiopathogenesis of *Sthaulya*.\[[@ref7]\] The patient of *Sthaulya* exhibits very strange phenomenon. Their appetite is excessive\[[@ref8]\] and whatever they eat is quickly digested, which indicates hyperfunctioning of the *Jatharaagni*. Besides this, the patient suffers from laziness, may be due to under supply of energy, which may be due to hypofunctioning of *Bhutaagni*. Further *Dhatvaagni* also seems to be disturbed, as in *Sthaulya* patient mainly *Medo-Dhatu* is formed and there is deficiency of other *Dhatu*.\[[@ref9]\] Hence, it can be inferred that in *Sthaulya, Jatharaagni* is *Tikshna, Bhutaagni* is *Manda* and *Dhatvaagni* is disturbed in their respective functions. On the basis of the above-mentioned facts of pathogenesis of *Sthaulya*, it can be said that the drug, which decreases *Jatharaagni* particularly *Abhyavaharana Shakti*, increases *Bhutaagni* and corrects the functions of *Dhatvaagni* and at the same time have *Medo-hara, Kapha-hara* and *Vatahara* actions, may be suitable for its management.

Taking all the above mentioned facts in consideration, *Agnimanthadi* compound comprising of *Agnimantha, Mustaka, Gomutra* and *Eranda Patra Kshara* was formulated for the present study. Most of these drugs are indicated in the treatment of *Sthaulya* in *Ayurvedic* classics.\[[@ref10]\]

*Agnimantha (Clerodendrum phlomidis* (Burm.f.) Kuntze) is *Dipana, Pachana, Kaphaghna, Shothahara* and is having *Vata-Kapha Hara properties*.\[[@ref11]\] Its antidiabetic action\[[@ref12]\] is also reported which may be due to its action at the level of *Bhutaagni* and *Dhatvaagni. Mustaka (Cyperus rotundus* Linn) has *Dipana, Pachana, Lekhana, Mutrala and Pitta Shamaka* actions.\[[@ref13]\] To make both drugs more *Tikshna*, seven *Bhavana* of *Gomutra* were given. *Gomutra* is *Tikshna, Ushna* and *Agni-Dipaka* in action\[[@ref14]\] and has *Kapha Vata Nashaka* properties. It is also indicated in the treatment of *Sthaulya* by *Sushruta*.\[[@ref7]\]

In clinical practice it is observed that *Agnimantha* produces burning sensation. Hence, *Eranda (Ricinus communis* Linn) *Patra Kshara* was added in the compound, which is reported to have *Kapha Nashaka, Medohara, Dipana* and *Pachana* actions.\[[@ref15]\]

Objective {#sec2-1}
---------

To evaluate the efficacy of *Agnimanthadi* compound in the management of *Sthaulya* (obesity)

Materials and Methods {#sec1-2}
=====================

The 83 patients of *Sthaulya* (obesity) attending the OPD and IPD of PG Hospital, IPGT and RA, Gujarat *Ayurveda* University, Jamnagar were registered for this study. Out of these, 15 patients were dropped out and 68 patients completed the prescribed course of the treatment.

Criteria of diagnosis {#sec2-2}
---------------------

The diagnosis was mainly based on the clinical presentation as mentioned in the *Ayurveda* texts as well as Allopathic texts along with body mass index (BMI). A detailed proforma incorporating all the clinical aspects mentioned for *Sthaulya*/obesity was prepared accordingly, detailed clinical history was taken and physical examination was done.

Criteria for selection of patients {#sec2-3}
----------------------------------

Patients in the age group of 16-65 years were selected for the present study. Other criteria for inclusion was as follow:

Subjective criteria {#sec2-4}
-------------------

Patients having clinical presentation of *Sthaulaya (obesity) as* mentioned in the *Ayurveda* texts as well as allopathic texts.

Objective criteria {#sec2-5}
------------------

For the present study BMI more than 30 was taken for considering the patients as obese and the patients having BMI 30-45 were included for the present study.

BMI calculated on the basis of height and weight of each patient, Standard range of normal body weight in relation to height mentioned by Life Insurance Corporation of India was adopted. An international criterion for BMI was used to calculate the BMI by the following formula:

BMI = weight (in kg)/Height (in meter).

Exclusion criteria {#sec2-6}
------------------

Patients in the age group of less than 16 years and more than 65 years were not included for the present study.Obese patients suffering from hypothyroidism, obesity due to hormonal imbalance, cardiovascular diseases, hemiplegia, associated with severe hypertension and from other such diseases in which the patient cannot do his routine physical activities were excluded.Very obese patients having BMI more than 45 were excluded from the present study.

Investigations {#sec2-7}
--------------

Lipid profile was carried out approximately in all the patients before and after the study and fasting blood sugar was carried out in suspected cases only.

Other examination and tests {#sec2-8}
---------------------------

Weight was recorded before starting the treatment and later on every week of the study. Weight was also recorded of all the patients who have come for the follow-up study.Circumferences of fatty parts were recorded before and thereafter every week, till the completion of the course of treatment, to assess the effect of therapy.The effectiveness of therapy on body fat was assessed by measuring the skin fold thickness by vernier calipers before and after the treatment in particular areas of middle portions of the biceps and triceps muscles, middle portion of the suprailiac region and the anterior surface of mid-thigh region and of abdominal muscle at umbilicus.Walking time: The time taken to climb fixed number of stairs in seconds was taken as walking time.

Groups division and treatment {#sec2-9}
-----------------------------

Eighty-three patients of *Sthaulya* were registered for this study and were divided into two groups' viz. Placebo control group and *Agnimanthadi* group. Out of which 15 patients were dropped out and 68 patients of *Sthaulya* completed the full-course of the treatment and their details were as follow:

Out of 68 patients of *Sthaulya* who completed the full-course of the treatment 30 patients were treated in the placebo control group and 38 patients were treated in *Agnimanthadi* group. This difference in number of patients in both the groups was due to more dropouts in the control group.

\(1\) Control (C) Group: The patients of this group were given two placebo capsules three times a day with lukewarm water before meal for seven weeks. Each capsule was filled with 500 mg of starch.

\(2\) *Agnimanthadi* (A) Group: Patients of this group were administered *Agnimanthadi* compound in the dose of 2 g (four capsules of 500 mg) three times a day with lukewarm water before meal for a period of 7 weeks.

Method of preparation of drug {#sec2-10}
-----------------------------

*Agnimanthadi* compound comprises of four drugs namely *Agnimantha, Mustaka, Eranda Patra Kshara* and *Gomutra*. First of all, fine powders of *Agnimantha* and *Mustaka* were taken in equal quantity. The mixture of these two powders was given seven *Bhavanas* of *Gomutra* and at the end *Eranda Patra Kshara* was added to it. Sixteen parts of *Gomutra Bhavita Agnimantha* and *Mustaka* was added to the one part of *Eranda Patra Kshara*. This compound was filled in the capsules.

Duration of treatment {#sec2-11}
---------------------

Duration of treatment for both the groups was 7 weeks.

Criteria of assessment {#sec2-12}
----------------------

The effect of therapy was assessed on the basis of the following subjective as well as objective criteria.

Subjective criteria {#sec2-13}
-------------------

A multidimensional scoring pattern was adopted for the sign and symptoms of *Sthaulya* mentioned in *Ayurvedic* texts. The score of symptom was assessed before and after the treatment and statistical analysis was undertaken. Apart from cardinal sign and symptom other signs and symptoms were also assessed. This assessment was done before starting the treatment and thereafter every week till completion of seven week course of therapy. The paired '*t*' test was applied for the statistical analysis of the results. Moreover assessment of *Dosha, Dushya, Srotasa* based on their dominant symptoms was also carried out.

Objective criteria {#sec2-14}
------------------

For objective criteria above mentioned parameters mentioned under the heading of investigations and examination and tests were taken into consideration.

Assessment of overall effect of the therapy {#sec2-15}
-------------------------------------------

For the overall assessment of the therapy following eight categories were taken into consideration:

Complete remission: 100% relief in the signs and symptoms, along with reduction in body weight up to normal range, for that particular height in comparison of age, was considered as complete remission.Marked improvement: More than 75% improvement noted in signs and symptoms, along with more than 75% weight reduction, was considered as markedly improved.Moderate improvement: Fifty to 75% improvement was noted in the sign and symptoms along with more then 50% weight reduction was considered as moderate improvement.Improvement: If 25-50% improvement was noted in the sign and symptoms along with more then 25% weight reduction, then it was considered as improvement.Slight improvement: Less than 25% relief in sign and symptoms along with less than 25% weight reduction was considered as slight improvement.Unchanged: No effect in sign and symptoms along with no change in weight was considered as unchanged.Deterioration: Increase in signs and symptoms or appearance of new symptoms or increase in weight was considered as deterioration.Change of score: If improvement was noted in sign and symptoms, but no improvement or mild increase of weight was recorded, then one step down improvement was assigned. Same was followed vice-versa.

Follow-up study {#sec2-16}
---------------

After completion of due course of treatment, all the patients were asked to report for follow-up study for the period of 2 months. In follow-up study statistical changes in body weight, chest circumference, hip circumference, abdomen circumference, abdomen skin fold measurement (SFM) and hip SFM were observed.

Observations {#sec2-17}
------------

In the present series of 83 patients of *Sthaulya* (obesity), maximum number of patients were in the age group of 21-50 years (74.69%), female (80.72%), Hindu by religion (65.1%), married (84.34%), belonging to lower middle socioeconomic class (51.81%) and were from urban habitat (98.8%).

In this series maximum number of patients were of *Kapha-Vata Prakriti* (50.60%) followed by *Kapha-Pitta Prakriti* (49.39%).

The 50.60% patients of this series were vegetarian, 69.88% were having habit of *Adhyashana*, 92.77% patients were doing sedentary work, 98.79% were not doing exercise at all, 84.34% patients were having sound sleep and 69.88% were jolly in nature.

Majority of the patients in this series i.e., 93.97% each were taking *Guru Guna* and *Shleshma Guna* dominant diet, 83.13% patients were satisfied only after ingestion of 50% more than their routine diet requirement and 43.37% of the patients were taking food 3-4 times in a day.

In this series all the patients were having the symptoms of *Sphika Chalatva* (100%), *Anga Gaurava* (100%), *Anga Shaithilya* (100%) and *Ati Kshudha* (100%). Other signs and symptoms observed were *Atipipasa* (93.97%), *Daurbalya* (92.77%), *Ayasena Shvasa* (91.6%), *Utsahahani* (92.77%), *Svedabadha (87*.95%), *Nidraadhikya* (84.34%), *Gatra Sada* (98.8) and *Udara Chalatva* (84.33%).

Main *Srotodushti* observed in patients of this series were *Medovaha* (100%), *Rasavaha* (98.79%), *Udakavaha* (97.59%), *Maajjavaha* (84.34%), *Pranavaha* (90.36%), *Svedavaha* (87.95%), *Annavaha* (78.31%), *Mutravaha* (62.65%) and *Purishvaha* (60.24%).

Maximum numbers of the patients were having Body weight in the range of 71-90 kg (60.24%) and BMI between 31 and 36 (50.60%). Maximum number of the patients i.e., 43.37% had 11-20 kg more weight than ideal body weight followed by 30.12% patients having 21-30 kg more weight than ideal body weight and 48.19% patients were suffering from *Sthaulya* from 5.1 to 10 years.

In this series maximum number of patients were having cholesterol in the range of 151-200 mgm/100 ml (54.2%), serum triglyceride in the range of 101-150 (30.12%), HDL in the range of 41-50 (37.25), LDL more than 150 (77.1%) and VLDL in the range of 21-30 (38.55%).

Effects of *Agnimanthadi* compound {#sec2-18}
----------------------------------

*Agnimahthadi* compound provided statistically highly significant reduction of 2.14% in the body weight and 1.86% in BMI \[[Table 1](#T1){ref-type="table"}\]. As shown in [Table 2](#T2){ref-type="table"} and [Figure 1](#F1){ref-type="fig"}, it provided statistically highly significant relief in *Utsaha Hani* (30.58%), *Daurbalyata* (28.41%), *Anga Gaurava* (25.67%), *Nindradhikya* (23.88%), *Gatra Sada* (22.05%) and *Aayasena Shvasa* (19.4%).

###### 

Comparison of the effects of therapies on body weight and BMI of 68 patients of *Sthaulya*

![](Ayu-32-241-g001)

###### 

Effect of *Agnimanthadi* compound on the sign and symptoms of 38 patients of *Sthaulya*

![](Ayu-32-241-g002)

![Effect of therapies on the symptoms of *Sthaulya*](Ayu-32-241-g003){#F1}

It provided statistically highly significantly reduction of 2.43% in increased pulse rate \[[Table 3](#T3){ref-type="table"}\], 4.71% in diastolic blood pressure \[[Table 4](#T4){ref-type="table"}\], 9.56% in serum cholesterol \[[Table 5](#T5){ref-type="table"}\], 4.98% in walking time \[[Table 6](#T6){ref-type="table"}\] and of 0.77% in total SFM \[[Table 7](#T7){ref-type="table"}\].

###### 

Comparison of the effects of therapies on pulse rate of 68 patients of *Sthaulya*

![](Ayu-32-241-g004)

###### 

Comparison of the effects of therapies on diastolic blood pressure of 68 patients of *Sthaulya*

![](Ayu-32-241-g005)

###### 

Comparison of the effects of therapies on lipid profi le of 68 patients of *Sthaulya*

![](Ayu-32-241-g006)

###### 

Comparison of the effects of therapies on walking time of 68 patients of *Sthaulya*

![](Ayu-32-241-g007)

###### 

Comparison of the effects of therapies on various SFM of 68 patients of *Sthaulya*

![](Ayu-32-241-g008)

It significantly reduced the systolic blood pressure by 1.68% \[[Table 8](#T8){ref-type="table"}\], the circumferences of Mid-arm by 2.70%, forearm by 2.70%, mid thigh by 1.91%, chest by 1.11%, abdomen by 1% and hip by 1% \[[Table 9](#T9){ref-type="table"} and [Figure 2](#F2){ref-type="fig"}\].

###### 

Comparison of the effects of therapies on systolic blood pressure of 68 patients of *Sthaulya*

![](Ayu-32-241-g009)

###### 

Comparison of the effects of therapies on various of 68 patients of *Sthaulya*

![](Ayu-32-241-g010)

![Effect of therapies on certain parameters of *Sthaulya*](Ayu-32-241-g011){#F2}

It provided statistically highly significant relief of 53.61% in *Sroto Dushti* symptoms of *Annavaha* and of 33.80% in *Rasavaha Srotasa* \[[Table 10](#T10){ref-type="table"}\]. It also significantly increased the symptom of *Ati Mutratata* by 25.39% \[[Table 2](#T2){ref-type="table"}\] which showed its diuretic effect.

###### 

Comparison of the effects of therapies on *Sroto Dushti* of 68 patients of *Sthaulya*

![](Ayu-32-241-g012)

The overall effect showed that *Agnimanthadi* compound provided moderate relief in 5.26%, Improvement in 13.16 and, slight improvement in 63.16% patients. In this group 5.26% patients remained Unchanged and 5.26% patients were further deteriorated \[[Table 11](#T11){ref-type="table"}\].

###### 

Overall effect of *Agnimanthadi* compound group on 38 patients of *Sthaulya*

![](Ayu-32-241-g013)

In follow-up study \[[Table 12](#T12){ref-type="table"}\], highly significant reduction (*P* \< 00.001) in body weight was observed in one month follow-up \[[Table 13](#T13){ref-type="table"}\]. But, this significant reduction was not sustained in the second month of follow-up study \[[Table 13](#T13){ref-type="table"}\].

###### 

Follow-up observation in the patients of *Sthaulya*

![](Ayu-32-241-g014)

###### 

Follow-up study of the patients of *Sthaulya in Agnimanthadi* compound group

![](Ayu-32-241-g015)

Effect of control group {#sec2-19}
-----------------------

Placebo in control group provided slight reduction in body weight and BMI but both the findings were not statistically significant \[[Table 1](#T1){ref-type="table"}\]. It provided significant relief in the symptoms of Daurbalyata (31.50%), *Utsaha Hani* (28.57%), *Aayasena Shvasa* (23.1%), *Anga Gaurava* (19.11%) and *Nidradhikya* (11.96%) as shown in [Table 14](#T14){ref-type="table"}. It significantly reduced diastolic blood pressure by 2.26% \[[Table 4](#T4){ref-type="table"}\] and ratio of Serum LDLC/HDLC by 16.55% and Serum TC/HDLC Ratio by 15.06% \[[Table 5](#T5){ref-type="table"}\]. It also provided significant relief in *Rasavaha Sroto Dushti* by 23.7% \[[Table 10](#T10){ref-type="table"}\].

###### 

Effect of control (placebo) on the sign and symptoms of 30 patients of *Sthaulya*

![](Ayu-32-241-g016)

Considering the overall effect showed that treatment with placebo provided improvement to 33.33% patients and slight improvement to 40%. In this group 6.67%. patients remained unchanged and 20% patients were further deteriorated \[[Table 15](#T15){ref-type="table"}\].

###### 

Overall effect of control group on 30 patients of *Sthaulya*

![](Ayu-32-241-g017)

Discussion {#sec1-3}
==========

In the present series, 83 patients fulfilling the criteria for the diagnosis of *Sthaulya* were selected. Out of which 15 patients had left the treatment at different stages. The remaining 68 patients completed full course of treatment for the period of 7 weeks, out of which 30 patients were in placebo control group and 38 patients were in *Agnimanthadi* compound group.

Comparison of the results of both the groups showed that *Agnimanthadi* compound provided better relief to the patients of *Sthaulya* than control group in the symptoms of *Utsaha Hani, Anga Gaurava, Nindradhikya, Gatra Sada, Snigdha Angata* and *Sveda Abadha*; and *Dushti Lakshana* of *Annavaha Srotasa* and *Rasavaha Srotasa*.

*Agnimanthadi* compound also imparted comparatively better and significant reduction \[[Table 1](#T1){ref-type="table"}\] in the body weight and BMI in comparison to the control group. It also showed comparatively better reduction on all circumferences of fatty parts of the body \[[Table 9](#T9){ref-type="table"}\] viz. biceps SFM, triceps SFM, suprailiac SFM and total SFM \[[Table 7](#T7){ref-type="table"}\], walking time \[[Table 6](#T6){ref-type="table"}\], pulse rate \[[Table 3](#T3){ref-type="table"}\] and diastolic blood pressure \[[Table 4](#T4){ref-type="table"}\].

It also provided comparatively better relief in serum cholesterol, serum LDL and serum LDLC/HDLC Ratio \[[Table 5](#T5){ref-type="table"}\].

On the other hand control group provided better relief in comparison to *Agnimanthadi* compound only in the two symptoms \[[Table 14](#T14){ref-type="table"}\] viz. *Daurbalayta* and *Ayasena Shvasa*. It also provided better effect on serum LDLC/HDLC ratio and serum TC/HDLC ratio \[[Table 15](#T15){ref-type="table"}\].

Comparison of the overall effects of the therapies {#sec2-20}
--------------------------------------------------

*Agnimanthadi* compound provided better improvement in overall signs and symptoms and laboratory findings related to *Sthaulya* in comparison to the Control group \[[Table 11](#T11){ref-type="table"} and [15](#T15){ref-type="table"}\] \[[Figure 3](#F3){ref-type="fig"}\].

![Overall effect of the therapies on the 68 patients of *Sthaulya*](Ayu-32-241-g018){#F3}

The results of the follow-up study showed, highly significant reduction (*P* \< 0.001) in body weight in one month follow-up \[[Table 13](#T13){ref-type="table"}\]. But, this significant reduction was not sustained in the second month of follow-up study \[[Table 13](#T13){ref-type="table"}\]. On the other hand no such effect was noticed in Placebo group at the follow-up study \[[Table 16](#T16){ref-type="table"}\].

###### 

Follow-up study of the patients of *Sthaulya* in control group

![](Ayu-32-241-g019)

*Agnimanthadi* compound comprises of *Agnimantha, Mustaka. Eranda Patra Kshara* and *Gomutra*, which are have *Dipana, Pachana, Medohara* and *Kaphahara* actions. Due to these properties of the drugs, *Agnimanthadi* Compound may have acted on hypo function of *Bhutagni* which was noticed by its significant effect on *Annavaha Srotaso Dushti* and on *Utsah Hani* and *Daurbalyata* which indicates it has effect at the level of *Bhutagni. Medohara* action of these drugs has provided significant effect on all the sign and symptoms of *Sthaulya*.

Conclusion {#sec1-4}
==========

The present placebo controlled clinical study was carried out on the patients of *Sthaulya* to evaluate the effects of *Agnimanthadi* compound administered orally in the dose of 2 g three times a day for 7 weeks. On the basis of the results of this study following conclusions may be drawn:

*Agnimanthadi* compound provided significant relief in the symptoms of *Ayasena Shvasa, Utsaha Hani, Daurbalyata, Nidra Adhikya, Sveda Abadha, Snigdha Angata, Angagaurava, Atipipasa* and *Ati-Kshudha*.*Agnimanthadi* compound significantly reduced the body weight and BMI of the patients of *Sthaulya*.*Agnimanthadi* compound provided significant relief in the *Dushti Lakshana* of *Annavaha Srotasa* and *Rasavaha Srotasa*.*Agnimanthadi* compound significantly reduced all the circumferences of fatty parts of the body viz. biceps SFM, triceps SFM, suprailiac SFM and total SFM.*Agnimanthadi* compound also significantly improved the walking time and reduced the increased pulse rate and diastolic blood pressure.*Agnimanthadi* compound also provided comparatively better relief in serum cholesterol, serum LDL, serum LDLC/HDLC ratio \[[Table 5](#T5){ref-type="table"}\].*Agnimanthadi* compound provided moderate relief in 5.26%, improvement in 13.16 and and slight improvement in 63.16% patients. In this group 5.26% patients remained unchanged and 5.26% patients were further deteriorated.In most of the cases the beneficial effects of *Agnimanthadi* compound were better in comparison to the placebo control group.
